<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164845">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01956097</url>
  </required_header>
  <id_info>
    <org_study_id>HX106</org_study_id>
    <nct_id>NCT01956097</nct_id>
  </id_info>
  <brief_title>Effects of HX106 on Improvement in Cognitive-Bio-Markers of Memory Function</brief_title>
  <official_title>Effects of HX106 on Improvement in Cognitive-Bio-Markers of Memory Function in Healthy Adults With Subjective Memory Complaints: An 8-Week Prospective Randomized Double-Blind Placebo-Controlled Trial With Multimodal Neuroimaging and Neurocognitive Assessments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ewha Womans University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ewha Womans University</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the current study are to evaluate the efficacy and safety of HX106 in
      healthy adults with subjective memory complaints for improving neurocognitive functions and
      to find the changes of brain using magnetic resonance imaging and their associations with
      the neurocognitive function enhancement.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changes from baseline in neurocognitive function</measure>
    <time_frame>Baseline, 8th weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in brain structure analyzed using the computational approach</measure>
    <time_frame>Baseline, 8th weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Morphometric analysis of brain structures in magnetic resonance imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in brain function analyzed using the computational approach</measure>
    <time_frame>Baseline, 8th weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood oxygenation level dependent (BOLD) signal intensity and their connectivity assessed using functional magnetic resonance imaging scans</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in brain biochemical metabolism analyzed using the computational approach</measure>
    <time_frame>Baseline, 8th weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Brain metabolite concentrations assessed using magnetic resonance spectroscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Subjective Memory Complaints Questionnaire scores at 8th weeks</measure>
    <time_frame>Baseline, 8th weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>1st week</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>4th weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>8th weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Healthy Adults With Subjective Memory Complaints</condition>
  <arm_group>
    <arm_group_label>HX106 590mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HX106 590mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HX106 1180mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HX106 1180mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>HX106 590mg</intervention_name>
    <arm_group_label>HX106 590mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>HX106 1180mg</intervention_name>
    <arm_group_label>HX106 1180mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 20 and 60 years old,

          -  Global Deterioration Scale score (GDS) of 2

          -  One or more symptoms of subjective memory impairment

          -  High school or higher levels of education.

        Exclusion Criteria:

          -  Current pregnancy or breast-feeding

          -  Evidence of neurologic or medical conditions

          -  Axis I diagnosis when assessed by the board certified psychiatrist using the
             Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental
             Disorder, 4th edition (DSM-IV)(SCID-IV),

          -  One or more major depressive episode during last 12 months

          -  Mini-mental status examination score of 24 or less

          -  Clinical Dementia Rating score of 0.5 or more suggesting cognitive impairment beyond
             self-perceived subjective deficits

          -  Intelligence quotient less than 80

          -  Any history of head trauma involving loss of consciousness or seizure

          -  Contraindications to magnetic resonance imaging (MRI)

          -  Use of psychotropics in last 3 months

          -  Use of oral contraceptive medication

          -  Participation in other clinical trials during the study period that might affect the
             outcome of the present study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In Kyoon Lyoo, MD, PhD, MMS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ewha W. University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jieun E Kim, MD, PhD</last_name>
    <phone>82-2-3277-6932</phone>
    <email>kjieun@ewha.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ewha W. University</name>
      <address>
        <city>Seoul</city>
        <zip>120-750</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyeonseok S Jeong, MS</last_name>
      <phone>82-2-3277-6929</phone>
      <email>alexhsjeong@gmail.com</email>
    </contact>
    <investigator>
      <last_name>In Kyoon Lyoo, MD, PhD, MMS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 1, 2013</lastchanged_date>
  <firstreceived_date>September 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ewha Womans University</investigator_affiliation>
    <investigator_full_name>In Kyoon Lyoo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
